Skip to Content
Merck
All Photos(1)

Documents

C2510000

Codergocrine mesilate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Ergoloid mesylate salt, Dihydroergotoxin mesylate salt

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

CAS Number:
8067-24-1
MDL number:
MFCD00209881
UNSPSC Code:
41116107
PubChem Substance ID:
329775009
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

codergocrine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CS(O)(=O)=O.CC(CO)NC(=O)C1CC2C(Cc3c[nH]c4cccc2c34)N(C)C1

InChI

1S/C19H25N3O2.CH4O3S/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13;1-5(2,3)4/h3-5,8,11,13,15,17,20,23H,6-7,9-10H2,1-2H3,(H,21,24);1H3,(H,2,3,4)

InChI key

ONYMVHQTXOEAOV-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Codergocrine mesilate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

[Can a hydergine therapy lead to damage of the coronary vessels?].
Frank Ulrich Müller
Deutsche medizinische Wochenschrift (1946), 127(25-26), 1401-1401 (2002-07-24)
Ursula Werneke et al.
The British journal of psychiatry : the journal of mental science, 188, 109-121 (2006-02-02)
The use of complementary medicines in those with mental health problems is well documented. However, their effectiveness is often not established and they may be less harmless than commonly assumed. To review the complementary medicines routinely encountered in psychiatric practice
A G Golden et al.
Journal of the American Geriatrics Society, 47(8), 948-953 (1999-08-12)
Little is known about the prescribing of medications in the growing population of homebound older adults. We report on the prevalence and pattern of inappropriate medications in a nursing home-eligible, homebound population. A cross-sectional design. A managed care plan for
B L Flynn et al.
The Annals of pharmacotherapy, 33(2), 188-197 (1999-03-20)
To provide information about research evaluating antioxidants in Alzheimer disease (AD) and to discuss the potential role of beta-blockers, angiotensin-converting enzyme inhibitors, clonidine, guanfacine, nimodipine, and ergoloid derivatives in AD therapy. Studies, review articles, and editorials identified from MEDLINE searches
J Olin et al.
The Cochrane database of systematic reviews, (2)(2), CD000359-CD000359 (2000-05-05)
Currently hydergine is used almost exclusively for treating patients with either dementia, or 'age-related' cognitive symptoms. Since the early eighties there have been over a dozen more clinical trials, yet hydergine's efficacy remains uncertain. Although previous reviews offer generally favorable
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service